Cart
sales@molnova.com
TAK-020
CAS No. 1627603-21-7
TAK-020( —— )
Catalog No. M37633 CAS No. 1627603-21-7
TAK-020 is a potent covalent inhibitor of Btk with potential antitumor activity for the study of rheumatoid arthritis and immune-related diseases.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 225 | In Stock |
|
| 5MG | 353 | In Stock |
|
| 10MG | 630 | In Stock |
|
| 25MG | 1260 | In Stock |
|
| 50MG | 1950 | In Stock |
|
| 100MG | 2952 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTAK-020
-
NoteResearch use only, not for human use.
-
Brief DescriptionTAK-020 is a potent covalent inhibitor of Btk with potential antitumor activity for the study of rheumatoid arthritis and immune-related diseases.
-
DescriptionTAK-020 is a covalent Btk inhibitor, which becomes the clinical candidate.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayTyrosine Kinase
-
TargetBTK
-
RecptorBTK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1627603-21-7
-
Formula Weight351.36
-
Molecular FormulaC18H17N5O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 20.83 mg/mL (59.28 mM; Ultrasonic (<80°C)
-
SMILESC=CC(=O)N1CC[C@@H](C1)Oc1nc(cc2ccccc12)-c1nc(=O)[nH][nH]1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Sabat M, et al. Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one, by Fragment-Based Drug Design. J Med Chem. 2021 Sep 9;64(17):12893-12902. ?
molnova catalog
related products
-
KS-99
KS-99 (KS99)?is a novel dual inhibitor of BTK and tubulin polymerization.
-
BTK-IN-16
BTK-IN-16 is a potential inhibitor of wild-type BTK and C481S mutants.BTK-IN-16 can be used to study various autoimmune diseases and cancers caused by BTK.
-
Vecabrutinib
Vecabrutinib (SNS-062) is a potent, reversible, non-covalent BTK inhibitor with IC50 of 2.9 and 4.4 nM for WT BTK and C481S BTK, respectively;
